Vendor Intelligence Report: Tianjin Eleli Technology Development

Executive summary

Tianjin Eleli is less a simple weak-vendor story than a narrow, uneven test record attached to an unusually tangled identity trail. Across 19 Finnrick lab tests, the vendor has 10 pass / 9 fail, for an overall pass rate of 53%. Retatrutide is the only relative bright spot, but it is compromised by a documented vial that contained no Retatrutide; GHK-Cu and Tirzepatide are fail-heavy, and stricter grading makes the read less forgiving.

The storefront presents a Tianjin peptide supplier, while HTML metadata, template paths, page titles, product-origin fields and a hidden mail target repeatedly point to a second Chinese operator. The claimed Tianjin address maps to a cultural-communications/advertising business rather than a pharma or chemical registrant, and the new domain record is Hebei-linked rather than Tianjin-linked.

Claims verification is also central. FDA registration or inspection, GMP qualification, ISO/HACCP language, U.S. warehouse availability and batch-level COA transparency were not substantiated in the searched records. The same storefront lists prescription and controlled-drug products alongside peptides, while support routes rely on free email, offshore phone numbers and dead or expired Discord invites.

The practical read is product-specific: Eleli is only arguable for Retatrutide with fresh batch-matched third-party verification. For GHK-Cu, Tirzepatide or untested catalog items, the current record points buyers toward vendors with cleaner product-specific histories.

Inside the full report:

• Appendix A Finnrick Laboratory Data with per-product pass/fail rates, methodology-divergence charts and the Retatrutide identity-failure timeline
• HTML-source vs rendered-page diff showing the Scardy/Eleli discrepancy, hidden mail target and QibuCore template path
• Domain, RDAP, DNS and hosting trace for ailailicn.com, including the cqscardy.com NXDOMAIN finding
• Claimed-address check, contact-geography analysis and Discord invite verification
• Regulated-catalog review and verification of FDA, GMP, ISO/HACCP, U.S. warehouse and COA claims
• Social account launch mapping plus reputation, forum and X/web affiliate sweeps

Risk assessment

• Retatrutide identity and consistency risk — high: Retatrutide has 11 Finnrick tests (8 pass / 3 fail), rating 76.24%, and a documented no-Retatrutide identity failure in a 30 mg vial.
• GHK-Cu and Tirzepatide fail-heavy testing risk — high: GHK-Cu and Tirzepatide each have 4 Finnrick tests with 1 pass / 3 fail; ratings are 73.36% and 69.66% respectively.
• Operating-entity concealment risk — high: The storefront presents Tianjin Eleli, while metadata, template paths, news content and product-origin records point to Chongqing Scardy and the Tianjin address matched an advertising firm.
• Misleading regulatory and certification claims risk — high: FDA registration/inspection, GMP, ISO22000, HACCP and ‘FDA certified’ claims lacked matching FDA records or certificate details.
• Regulated-drug catalog risk — high: The same storefront lists Superdrol, Tadalafil, Sildenafil, Proviron and Flibanserin alongside research peptides.
• Support-channel reliability risk — medium: Both Discord invites were dead or expired; contact routes rely on free email, WhatsApp and inconsistent Hong Kong/Vietnam numbers.
• Unverified US warehouse and logistics claims risk — medium: No US corporate registration, warehouse address or ImportYeti shipment record was found for Tianjin Eleli or Scardy.
• Thin public track-record risk — medium: ailailicn.com was registered 2025-09-16, with no pre-registration Wayback history and no Trustpilot, Reddit or GLP1Forum reputation base found.